New Fingerstick Test Beats Lab Delays for Hep B

A world-first Australian trial has demonstrated that a simple fingerstick test for hepatitis B DNA is as accurate as standard laboratory testing. This point-of-care innovation, published in the Journal of Clinical Microbiology, can provide results within an hour and be performed in decentralized clinics. The fingerstick test is expected to overcome the delays and travel challenges inherent in laboratory-based testing.

Professor Gail Matthews of the Kirby Institute at the University of New South Wales led the research, highlighting the test's high accuracy and its potential to expand global access to testing and treatment. Hepatitis B affects an estimated 254 million people worldwide, causing over one million deaths annually. Current diagnostic and monitoring methods require venous blood samples sent to central labs, often involving long patient waits and multiple clinic visits.

The new fingerstick test uses a small blood sample and can be administered by a wider range of healthcare workers, offering results in 60 minutes. This development is seen as a significant step towards meeting the WHO's 2030 target of eliminating hepatitis B as a public health threat.